Evidence for the efficacy of enzalutamide in postchemotherapy metastatic castrate-resistant prostate cancer.

ABSTRACT: The treatment of metastatic castrate-resistant prostate cancer (mCRPC) has evolved rapidly with the recent approval of a number of treatments and agents, including docetaxel, sipuleucel T, abiraterone, cabazitaxel, and enzalutamide. Enzalutamide (previously MDV-3100) is a novel oral androgen receptor inhibitor that targets multiple steps in the androgen receptor signaling pathway. The randomized phase III AFFIRM study demonstrated significant improvements in a number of efficacy endpoints, including the primary endpoint of overall survival and secondary endpoints of progression-free survival, and time to prostate-specific antigen progression in patients with progressive mCRPC who had received prior treatment with docetaxel. Enzalutamide was well tolerated and there were comparable incidenc

SUBMITTER: Saad F 

PROVIDER: S-EPMC3721441 | biostudies-literature | 2013 Aug

REPOSITORIES: biostudies-literature